OBJECTIVE: To evaluate Transforming Growth Factor b b 1 (TGF-b b 1 ) plasma concentrations and the possible relationship between this growth factor and various hormones in obese women. DESIGN: Case-control study. SETTING: Outpatient's Service for the Prevention and Treatment of Obesity at the University Hospital. SUBJECTS: Twenty-®ve women with mild to moderate obesity, and 15 non-obese healthy women were used as controls. MEASUREMENTS: Evaluation of TGF-b b 1 , insulin, prolactin, sex-hormone binding globulin, androstenedione, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, dehydroepiandrosterone-sulfate, testosterone, insulin-like growth factor 1, cortisol and adrenocorticotropic hormone plasma concentrations in obese women. Blood samples were taken from fasting subjects for the determination of the above parameters. RESULTS: In obese women plasma TGF-b b 1 concentrations were lower than in controls. The obese subjects also had lower GH, IGF-1 and SHBG plasma concentrations and increased insulinaemia. A positive correlation was found between TGF-b b 1 and both IGF-1 (r 0.52; P`0.01) and DHEA-S (r 0.43; P`0.05), while a negative correlation was found between TGF-b b 1 and SHBG (r 70.49; P`0.05). CONCLUSIONS: The reduction in TGF-b b 1 , an antilipogenic factor, may play a role in the pathogenesis of obesity and could be involved in the development of some obesity-related endocrine alterations.
Introduction
Unlike many endocrine factors (such as insulin, triiodothyronine and Insulin-like Growth Factor-1), which appear to enhance the formation of new adipose cells, growth factors are generally considered to have an inhibitory effect on adipocyte differentiation. 1 The growth factors, interferon g, interleukin-1 and the Epidermal Growth Factor have, in fact, an antiadipogenic effect. 1 Moreover, TGF-b also exerts an analogous action and can inhibit the differentiation of human and rat preadipocytes in culture. 2±6 These growth factors are in fact known to be potent stimulators of the synthesis of collagen and proteoglycans and modulators of the extracellular matrix arrangement, and seem capable of blocking the differentiation of preadipocyte cell lines such as 3T3, TA1 and Ob1771. Although the action of TGF-b on embryonic cells does not exactly re¯ect events occurring in vivo, other authors have shown in animal models that it has an analogous effect on adipose tissue. 7, 8 TGF-b thus seems to block the transition of cells from the undifferentiated to the differentiated state, where the adipocyte phenotype is fully expressed. 9 Our aim was therefore to evaluate plasma TGF-b 1 concentrations in obese patients. Moreover, as it has been demonstrated that TGF-b can intervene in the regulation of the synthesis of numerous hormones, 10 in the same subjects we evaluated several hormone concentrations in order to ascertain whether altered TGF-b 1 concentrations are responsible for the endocrine alterations frequently found in the obese.
Methods

Patients and controls
Our study was conducted on 25 women with mild to moderate obesity and regular menstrual cycles (age 33.1 AE 5.4 y, BMI 32.3 AE 4.3 kg/m 2 , WHR 0.86 AE 0.03). The criteria used by us to de®ne obesity were those suggested by the WHO (BMI for obese women higher than 28.6 kg/m 2 ).
11 Body height was measured without shoes to the nearest 0.5 cm; body weight was measured without clothes to the nearest 0.1 kg; body mass index (BMI) was measured as weight/height 2 (kg/m 2 ); waist circumference was measured midway between the lower rib margin and the iliac crest, hip circumference was determined as the widest circumference measured over the great trochanters. The waist to hip ratio (WHR) was then calculated. 12 Other endocrine and metabolic diseases were ruled out on the basis of physical examination and laboratory tests. In particular, none of the subjects had adrenal disease or hirsutism. The patients had neither taken drugs for at least one month before the study, nor were they on special diets. The control group consisted of 15 non-obese healthy women (age 31.4 AE 2.7 y, BMI 20.8 AE 1.6 kg/m 2 ), with regular menstrual cycles. All tests were begun in the morning, between 08.00 and 09.00 am, after a 12 h overnight fast, and 30 min after cannulation of a cubital vein kept patent by slow infusion of isotonic saline solution, in the follicular phase, and plasma samples were stored at 770 C.
Laboratory methods and hormonal assays
In all the samples, the following parameters were assayed: plasma insulin ( 
TGF-b 1 bioassay
Plasma TGF-b 1 bioassay was performed by Elisa kit (Predicta TGF-b 1 kit, Genzyme Diagnostics, Cambridge, MA, USA) using immobilized mouse monoclonal antibody to TGF-b 1 . The inter-assay variation for the TGF-b 1 method is 5.2% at 1.44 ng/ml and 4.8% at 3.1 ng/ml. The intra-assay variation is 5.2% and 4.8% respectively. The sensitivity is 0.05 ng/ml. The range of the expected values is 28±157 ng/ml.
Statistical analysis
The statistical analysis was performed using ANOVA one-way test because data values for TGF-b 1 in the population studied were normally distributed (Sha- 
Results
In the group studied, plasma TGF-b 1 concentrations were found to be markedly lower than in controls (104.7 AE 49.1 vs 167.2 AE 24.5 ng/ml; P`0.01) (Figure 1) . The obese subjects also had lower concentrations of GH, IGF-1, and SHBG, and increased insulinaemia ( Table 1 ).
In the group of obese subjects, a positive correlation was found between TGF-b 1 and IGF-1 (r 0.52; P`0.01), and between TGF-b 1 and DHEA-S (r 0.43; P`0.05), while a negative correlation was found between TGF-b 1 and SHBG (r 70.49; P`0.05). Moreover, in the same group, we found a negative correlation between SHBG and BMI (r 70.44; P`0.05), and between SHBG and IGF-1 (r 70.40; P`0.05). Plasma insulin was positively correlated both with WHR and WC. A positive correlation was also found between DHEA-S and IGF-1 ( Table 2) . No correlation was found in the control group.
The multiple linear regression analysis performed in the group of obese women, considering TGF-b 1 as an independent variable, indicated that IGF-1 and DHEA-S increase together with TGF-b 1 , while SHBG decreases (Table 3) .
Discussion
The most important ®nding in our study was a marked reduction in plasma TGF-b 1 concentrations in obese patients. As in vitro studies have shown that this growth factor inhibits the differentiation of adipocytes, 2±6 the reduction found in obese women may play an important role in the pathogenesis and maintenance of obesity. Moreover, our ®ndings con®rm those made by other authors in subjects with obesity: a reduction in concentrations of GH 13 , IGF-1, 14 and SHBG, 15 and a correlation between the latter and the degree of obesity. Unlike Weaver et al, 16 we found a negative correlation between IGF-1 and SHBG. It should, however, be borne in mind that Weaver's study was conducted on women with severe obesity and a high incidence of infertility. The ®nding of an inverse correlation between IGF-1 and SHBG is also con®rmed by the fact that IGF-1 appears to inhibit the hepatic synthesis of SHBG. 17 We found a negative correlation between TGF-b 1 and SHBG, a known marker of insulin resistance. 18 Although the lack of a correlation between TGF-b 1 and insulin precludes any de®nitive conclusion regarding the relations between TGF-b 1 concentrations and insulin-resistance status, it is important to point out that basal values for plasma insulin are sometimes inappropriate for the de®nition of this condition, as the sensitivity of insulin is highly variable. 19 Moreover, in our study we showed also a positive correlation between TGF-b 1 and IGF-1, a hormone that in some experimental models in vitro can regulate some TGF-b isoforms, through a reduction in its expression. 20 Findings in vivo and in obese patients might, however, be different. Moreover, the variations in TGF-b 1 found in obese women may be important in *P`0.001; **P`0.01; ***P`0.05 vs control group (ANOVA one-way test).
TGF-b b 1 in obese patients F Corica et al determining the modi®cations in adrenal function frequently found in these subjects. 21±23 In bovine adrenal cells, in fact, TGF-b 1 inhibits cortisol production. This hypothesis is not contradicted by our ®nding that cortisol values in the obese patients were identical to those in the controls. It is in fact known that the normal plasma cortisol concentrations found in obese subjects are due to an increased metabolic clearance of the hormone. 24 Finally, no variation with respect to the control group was found for DHEA-S, a hormone presumed to have an antiadipogenic action, inhibiting the abdominal accumulation of adipose tissue, 25 although a positive correlation was found by us between this hormone and TGF-b 1 .
Moreover, the results of multiple linear regression analysis seem to con®rm our hypothesis of a possible pathogenetic role of TGF-b 1 in the endocrine changes frequently observed in obesity. In fact, the correlations found between TGF-b 1 and SHBG, DHEA-S and IGF-1 were con®rmed only when we considered TGF-b 1 as an independent variable.
Conclusions
Our data indicate that there are important variations in the plasma concentrations of TGF-b 1 in obese women. These modi®cations in the only adipogenic agent capable of completely blocking the recruitment of preadipocytes and their differentiation (to a greater extent than other substances with an antiadipocyte effect, such as TNF-a, the submaxillary gland kallikrein and PGF 2a ) 26 are probably signi®cant in the pathogenesis of obesity itself.
A deeper understanding of the mechanisms underlying the variations in the plasma concentrations of the growth factor in obese subjects, and the study of the effects of these modi®cations, will provide further insight on the pathophysiology of obesity.
